Two series of peptides, designated K and NK were synthesized and tested for lipid A binding and neutralizing properties. K2, which has an 11-residue amphiphilic core, and a branched N-terminus bearing two branched lysinyl residues does not bind lipid A, while NK2, also with an 11-residue amphiphilic core comprised entirely of non-ionizable residues, and a similarly branched, cationic N-terminus, binds lipid A very weakly. Both peptides do not inhibit lipopolysaccharide (LPS) activity in the Limulus assay, nor do they inhibit LPS-induced TNF-α and NO production in J774 cells. These results are entirely unlike a homologous peptide with an exclusively hydrophobic core whose LPS-binding and neutralizing properties are very similar to that of polymyxin B [David SA, Awasthi SK, Wiese A et al. Characterization of the interactions of a polycationic, amphiphilic, terminally branched oligopeptide with lipid A and lipopolysaccharide from the deep rough mutant of Salmonella minnesota . J Endotoxin Res 1996; 3: 369—379]. These data suggest that a clear segregation of charged and apolar domains is crucial in molecules designed for purposes of LPS sequestration and that head-tail (polar) orientation of the cationic/hydrophobic regions is preferable to molecules with mixed or facial cationic/amphipathic character.
References
1.
Raetz Crh.Biochemistry of endotoxins. Annu Rev Biochem1990; 59: 129—170.
2.
Morrison DC, Ryan JLEndotoxins and disease mechanisms. Annu Rev Med1987; 38: 417—432.
3.
Rietschel ET , Kirikae T., Schade FU et al. Bacterial endotoxin: molecular relationships of structure to activity and function. FASEB J1994; 8: 217—225.
4.
Evans TJThe role of macrophages in septic shock. Immunobiology1996; 195: 655—659.
5.
Tracey KJ, Cerami A.Tumor necrosis factor: an updated review of its biology. Crit Care Med1993; 21: S415—S422.
6.
Dinarello CACytokines as mediators in the pathogenesis of septic shock. Curr Top Microbiol Immunol1996 ; 216: 133—165.
7.
Wright CE, Rees DD, Moncada S.Protective and pathological roles of nitric oxide in endotoxin shock. Cardiovasc Res1992; 26: 48—57.
8.
Lefer AMEndotoxin, cytokines, and nitric oxide in shock [Editorial]. Shock1994; 1: 79—80.
9.
Parrillo JEPathogenic mechanisms of septic shock. N Engl J Med1993; 328: 1471—1477.
10.
Bone RCThe sepsis syndrome. Definition and general approach to management. Clin Chest Med1996; 17: 175—181.
11.
Bone RCGram-negative sepsis: a dilemma of modern medicine. Clin Microbiol Rev1993; 6: 57—68.
12.
Siegel JPAntiendotoxin antibodies. Ann Intern Med1995 ; 122: 315—316.
13.
Cross AS, Opal S.Therapeutic intervention in sepsis with antibody to endotoxin: is there a future?J Endotoxin Res1994; 1: 57—69.
14.
Ziegler EJ, McCutchan JA, Fierer J. et al. Treatment of Gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli. N Engl J Med1982; 307: 1225—1230.
15.
Baumgartner JD, Glauser MP, McCutchan JA et al. Prevention of Gram-negative shock and death in surgical patients by antibody to endotoxin core glycolipid. Lancet1985; ii: 59—63.
16.
Cross ASAntiendotoxin antibodies: a dead end. Ann Intern Med1994; 121: 58—60.
17.
Evans TJ, Carpenter A., Moyes D., Martin R., Cohen J.Protective effects of a recombinant amino-terminal fragment of human bactericidal/permeability-increasing protein in an animal model of Gram-negative sepsis. J Infect Dis1995; 171: 153—160.
18.
von der Mohlen MA, Kimmings AN, Wedel NI et al. Inhibition of endotoxin-induced cytokine release and neutrophil activation in humans by use of recombinant bactericidal/permeability-increasing protein. J Infect Dis1995; 172: 144—151.
19.
Appelmelk BJ, An Y-Q., Thijs BG, MacLaren DM, De Graaff J.Recombinant human bactericidal/permeability-increasing protein (rBPI23) is a universal lipopolysaccharide-binding ligand. Infect Immun1994; 62: 3564—3567.
20.
Marra MN, Thornton MB, Snable JL, Wilde CG, Scott RWEndotoxin-binding and -neutralizing properties of recombinant bactericidal/permeability-increasing protein and monoclonal antibodies HA-1A and E5. Crit Care Med1994; 22: 559—565.
21.
Gazzano-Santoro H., Parent JB, Grinna L. et al. High-affinity binding of the bactericidal/permeability-increasing protein and a recombinant amino-terminal fragment to the lipid A region of lipopolysaccharide. Infect Immun1992; 60: 4754—4761.
22.
Ooi CE, Weiss J., Doerfler ME, Elsbach P.Endotoxin-neutralizing properties of the 25 kDa N-terminal fragment and a newly isolated 30 kDa C-terminal fragment of the 55—60 kDa bactericidal/permeability-increasing protein of human neutrophils. J Exp Med1991 ; 174: 649—655.
23.
Marra MN, Wilde CG, Griffith JE, Snable JL, Scott RWBactericidal/permeability-increasing protein has endotoxin-neutralizing activity . J Immunol1990; 144: 662—666.
24.
Fletcher MA , McKenna TM, Quance JL, Wainwright NR, Williams TJLipopolysaccharide detoxification by endotoxin neutralizing protein. J Surg Res1993; 55: 147—154.
25.
Nelson D., Kuppermann N., Fleisher GR et al. Recombinant endotoxin neutralizing protein improves survival from Escherichia coli sepsis in rats. Crit Care Med1995; 23: 92—98.
26.
Kuppermann N., Nelson DS, Saladino RA et al. Comparison of a recombinant endotoxin-neutralizing protein with a human monoclonal antibody to endotoxin for the treatment of Escherichia coli sepsis in rats. J Infect Dis1994; 170: 630—635.
27.
Garcia C., Saladino R., Thompson C. et al. Effect of a recombinant endotoxin-neutralizing protein on endotoxin shock in rabbits. Crit Care Med1994; 22: 1211—1218.
28.
David SA, Mathan VI, Balaram P.Interaction of melittin with endotoxic lipid A. Biochim Biophys Acta1992; 1123: 269—274.
29.
David SA, Bechtel B., Annaiah C., Mathan VI, Balaram P.Interaction of cationic amphiphilic drugs with lipid A: implications for development of endotoxin antagonists. Biochim Biophys Acta1994; 1212: 167—175.
30.
David SA, Balaram P., Mathan VIInteraction of basic amphiphilic polypeptide antimicrobials, gramicidin S, tyrocidin and efrapeptin, with endotoxic lipid A. Med Microbiol Lett1993; 2: 42—47.
31.
David SA, Bechtel B., Anniah C., Mathan VI, Balaram P.Interaction of cationic amphiphilic drugs with lipid A: Implications for development of endotoxin antagonists. Biochim. Biophys. Acta1994; 1212: 167—175.
32.
David SA, Mathan VI, Balaram P.Interactions of linear dicationic molecules with lipid A: structural features that correspond to optimal binding affinity. J Endotoxin Res1995; 2: 325—336.
33.
Rustici A., Velucchi M., Faggioni R. et al. Molecular mapping and detoxification of the lipid A binding site by synthetic peptides. Science1993; 259: 361—365.
34.
Porro M.Structural basis of endotoxin recognition by natural polypeptides. Trends Microbiol1994; 2: 65—66.
35.
Iwagaki A., Porro M., Pollack M.Influence of synthetic antiendotoxin peptides on lipopolysaccharide (LPS) recognition and LPS-induced pro-inflammatory cytokine responses by cells expressing membrane-bound CD-14. Infect Immun2000; 68: 1655—1663.
36.
Storm DR, Rosenthal K.Polymyxin and related peptide antibiotics. Annu Rev Biochem1977; 46: 723—763.
37.
David SA, Balasubramanian KA, Mathan VI, Balaram P.Analysis of the binding of polymyxin B to endotoxic lipid A and core glycolipid using a fluorescent displacement probe. Biochim Biophys Acta1992; 1165: 147—152.
38.
Bhattacharjya S., David SA, Mathan VI, Balaram P.Polymyxin B nonapeptide: conformations in water and in the lipopolysaccharide-bound state determined by two-dimensional NMR and molecular dynamics. Biopolymers1997 ; 41: 251—265.
39.
Stokes DC, Shenep JL, Fishman ML, Hidner WK, Bysani GK, Rufus K.Polymyxin B prevents lipopolysaccharide-induced release of tumor necrosis factor-α from alveolar macrophages. J Infect Dis1989; 160: 52—57.
40.
Aoki H., Kodama M., Tani T., Hanasawa K.Treatment of sepsis by extracorporeal elimination of endotoxin using polymyxin B-immobilized fiber. Am J Surg1994; 167: 412—417.
41.
Morrison DC , Jacobs DMBinding of polymyxin B to the lipid A portion of bacterial lipopolysaccharides. Immunochemistry1976; 13: 813—818.
42.
David SA, Awasthi SK, Wiese A. et al. Characterization of the interactions of a polycationic, amphiphilic, terminally branched oligopeptide with lipid A and lipopolysaccharide from the deep rough mutant of Salmonella minnesota. J Endotoxin Res1996; 3: 369—379.
43.
Behr J-P.Gene transfer with synthetic cationic amphiphiles: prospects for gene therapy . Bioconjug Chem1994; 5: 382—389.
David SA, Silverstein R., Amura CR, Kielian T., Morrison DCLipopolyamines: novel antiendotoxin compounds that reduce mortality in experimental sepsis caused by Gram-negative bacteria. Antimicrob Agents Chemother1999; 43: 912—919.
46.
Bach D., Miller IRInteraction of bilayers with basic polypeptides. J Membr Biol1973; 11: 237—254.
47.
Kaiser ET, Kezdy FJPeptides with affinity for membranes. Annu Rev BiophysBiophys Chem1987; 16: 561—581.
48.
Eisenberg D. , Wilcox W., McLachlan ADHydrophobicity and amphiphilicity in protein structure. J Cell Biochem1986; 31: 11—17.
49.
Eisenberg D. , Weiss RM, Terwilliger TCThe hydrophobic moment detects periodicity in protein hydrophobicity. Proc Natl Acad Sci USA1984; 81: 140—144.
50.
Cornette JL , Cease KB, Margalit H., Spouge JL, Berzofsky JA, DeLisi C.Hydrophobicity scales and computational techniques for detecting amphipathic structures in proteins. J Mol Biol1987; 195: 659—685.
51.
Eisenberg D. , Weiss RM, Terwilliger TCThe helical hydrophobic moment: a measure of the amphiphilicity of a helix. Nature1982 ; 299: 371—374.
52.
Schiffer M. , Edmundson ABUse of helical wheels to represent the structures of protein and to identify segments with helical potential. Biophys J1967; 7: 121—135.
53.
Baldwin RLα-Helix formation by peptides of defined sequence. Biophys Chem1995; 55: 127—135.
54.
Chakrabartty A., Baldwin RLStability of α-helices. Adv Prot Chem1995; 46: 141—176.
55.
Lyu PC, Liff MI, Marky LA, Kallenbach NRSidechain contributions to the stability of α-helical structures in peptides . Science1990; 250: 669—673.
56.
Scholtz JM, Baldwin RLThe mechanism of α-helix formation by peptides. Annu Rev Biophys Biomol Struct1996; 21: 95—118.
57.
Green LC, Wagner DA, Glogowski J., Skipper PL, Wishnok JS, Tannenbaum SRAnalysis of nitrate, nitrite and [15N]-nitrate in biological fluids. Anal Biochem1982; 126: 131—138.
58.
David SAAnalysis of the desirable structural properties in potential endotoxin antagonists . PhD Thesis 1995; Madras University, Christian Medical College Hospital, Vellore, India
59.
Danner RL, Joiner KA, Rubin M. et al. Purification, toxicity, and anti-endotoxic activity of polymyxin B nonapeptide. Antimicrob Agents Chemother1989; 33: 1428—1434.
60.
David SA, Balaram P., Mathan VICharacterization of the interaction of lipid A and lipopolysaccharide with human serum albumin: implications for an endotoxin-carrier function for albumin . J Endotoxin Res1995; 2: 99—106.
61.
Din ZZ, Mukerjee P., Kastowsky M., Takayama K.Effect of pH on solubility and ionic state of lipopolysaccharide obtained from the deep rough mutant of Escherichia coli. Biochemistry1993; 32: 4579—4586.
62.
van Veen M., Georgiou GN, Drake AF, Cherry RJCircular-dichroism and fluorescence studies on melittin: effects of C-terminal modifications on tetramer formation and binding to phospholipid vesicles. Biochem J1995; 305: 785—790.
63.
Ohman A., Davydov R., Backlund BM, Langel U., Graslund A.A study of melittin, motilin and galanin in reversed micellar environments, using circular dichroism spectroscopy. Biophys Chem1996; 59: 185—192.
64.
Smith LJ, Clark DCMeasurement of the secondary structure of adsorbed protein by circular dichroism. 1. Measurements of the helix content of adsorbed melittin. Biochim Biophys Acta1992; 1121: 111—118.
65.
Takahashi T.Significant role of electrostatic interactions for stabilization of protein assemblies. Adv Biophys1997; 34: 41—54.
66.
Schnitzer JE , Lambrakis KCElectrostatic potential and Born energy of charged molecules interacting with phospholipid membranes: calculation via 3-D numerical solution of the full Poisson equation. J Theor Biol1991; 152: 203—222.
67.
Moore KS, Wehrli S., Roder H. et al. Squalamine: an aminosterol antibiotic from the shark. Proc Natl Acad Sci USA1993; 90: 1354—1358.
68.
Moriarty RM , Tuladhar SM, Guo L., Wehrli S.Synthesis of squalamine, a steroidal antibiotic from the shark. Tetrahedron Lett1994; 35: 8103—8106.
69.
Kikuchi K., Bernard EM, Sadownik A., Regen SL, Armstrong D.Antimicrobial activities of squalamine mimics. Antimicrob Agents Chemother1997; 41: 1433—1438.
70.
Sadownik A. , Deng G., Janout V., Regen SLRapid construction of a squalamine mimic. J Am Chem Soc1995; 117: 6138—6139.
71.
Li C., Budge LP, Driscoll CD, Willardson BM, Allman GW, Savage PBIncremental conversion of outer-membrane permeabilizers into potent antibiotics for Gram-negative bacteria. J Am Chem Soc1999; 121: 931—934.
72.
Li C., Lewis MR, Gilbert AB et al. Antimicrobial activities of amine- and guanidine-functionalized cholic acid derivatives. Antimicrob Agents Chemother1999; 43: 1347—1349.
